A genetic model of ivabradine recapitulates results from randomized clinical trials.

Marc-André LegaultJohanna SandovalSylvie ProvostAmina BarhdadiLouis-Philippe Lemieux Perreault Sonia Shah R Thomas LumbersSimon de DenusBenoit TylJean-Claude TardifMarie-Pierre Dubé

Published in: PloS one (2020)

Genetic modelling of ivabradine recapitulates its benefits in heart failure, promotion of atrial fibrillation, and neutral effect on myocardial infarction.

Keyphrases

heart failure
atrial fibrillation
heart rate
genome wide
left ventricular
copy number
left atrial
oral anticoagulants
clinical trial
catheter ablation
left atrial appendage
cardiac resynchronization therapy
coronary artery disease
dna methylation
mitral valve
venous thromboembolism